Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
Authors
Keywords
Pancreatic cancer, Gemcitabine resistant, CXCR4, CXCL12, CXCR4 antagonist
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-05-12
DOI
10.1186/s12885-016-2340-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stromal Cell-derived Factor-1 and its Receptor CXCR4 are Upregulated Expression in Degenerated Intervertebral Discs
- (2014) Hua Zhang et al. International Journal of Medical Sciences
- Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
- (2013) G O'Boyle et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An Undesired Effect of Chemotherapy
- (2013) Sumit Arora et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Role of CXCL12-CXCR4 Signaling Pathway in Pancreatic Development
- (2013) Keiichi Katsumoto et al. Theranostics
- The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor
- (2011) Renee M. Mosi et al. BIOCHEMICAL PHARMACOLOGY
- Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist
- (2011) R Parameswaran et al. LEUKEMIA
- CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
- (2010) S Singh et al. BRITISH JOURNAL OF CANCER
- CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
- (2010) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
- (2010) Renato T. Skerlj et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100
- (2009) T. Murakami et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
- (2009) R Maréchal et al. BRITISH JOURNAL OF CANCER
- 3,3′-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer
- (2009) Sanjeev Banerjee et al. CANCER RESEARCH
- Pancreatic cancer: molecular pathogenesis and new therapeutic targets
- (2009) Han H. Wong et al. Nature Reviews Gastroenterology & Hepatology
- Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression
- (2008) R. F. Hwang et al. CANCER RESEARCH
- CXCL8/IL-8 and CXCL12/SDF-1α co-operatively promote invasiveness and angiogenesis in pancreatic cancer
- (2008) Yoichi Matsuo et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started